NCT05238883 - A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | Biotech Hunter

Enrollment

170

Participants

Timeline

Start Date

March 10, 2022

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2026

Conditions

Gastric CancerRenal Cell CarcinomaMelanomaSarcomaTesticular Germ Cell TumorCervical CancerMesotheliomaNon Small Cell Lung CancerHead and Neck Squamous Cell Carcinoma

Interventions

DRUG

HFB200301

Participants will be administered HFB200301 as described in the experimental arm.

DRUG

Tislelizumab

Participants will be administered tislelizumab as described in the experimental arm.

Trial Locations (10)

22031

RECRUITING

NEXT Virginia Cancer Specialists, Fairfax

28041

RECRUITING

Hospital Universitario 12 de Octubre, Madrid

32224

RECRUITING

Mayo Clinic, Jacksonville

46010

RECRUITING

Hospital Clinico Universitario de Valencia, Valencia

55905

ACTIVE_NOT_RECRUITING

Mayo Clinic, Rochester

63110

RECRUITING

Washington University School of Medicine, St Louis

77030

TERMINATED

The University of Texas, MD Anderson Cancer Center, Houston

85259

ACTIVE_NOT_RECRUITING

Mayo Clinic, Scottsdale

90033

RECRUITING

USC/Norris Comprehensive Cancer Center, Los Angeles

08035

RECRUITING

Hospital Universitario Vall d'Hebron, Barcelona